Cargando…
Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226289/ https://www.ncbi.nlm.nih.gov/pubmed/37269750 http://dx.doi.org/10.1016/j.leukres.2023.107330 |
| _version_ | 1785050547087212544 |
|---|---|
| author | Atanasio, A. Vanni, A. Maggi, L. Pilerci, S. Mazzoni, A. Capone, M. Crupi, F. Cicogna, P. Boldrini, V. Tekle, S. Colao, M.G. Borella, M. Paoli, C. Rossolini, G.M. Vannucchi, A.M. Annunziato, F. Guglielmelli, P. |
| author_facet | Atanasio, A. Vanni, A. Maggi, L. Pilerci, S. Mazzoni, A. Capone, M. Crupi, F. Cicogna, P. Boldrini, V. Tekle, S. Colao, M.G. Borella, M. Paoli, C. Rossolini, G.M. Vannucchi, A.M. Annunziato, F. Guglielmelli, P. |
| author_sort | Atanasio, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10226289 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102262892023-05-30 Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy Atanasio, A. Vanni, A. Maggi, L. Pilerci, S. Mazzoni, A. Capone, M. Crupi, F. Cicogna, P. Boldrini, V. Tekle, S. Colao, M.G. Borella, M. Paoli, C. Rossolini, G.M. Vannucchi, A.M. Annunziato, F. Guglielmelli, P. Leuk Res Letter to Editor Elsevier Ltd. 2023-08 2023-05-29 /pmc/articles/PMC10226289/ /pubmed/37269750 http://dx.doi.org/10.1016/j.leukres.2023.107330 Text en © 2023 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to Editor Atanasio, A. Vanni, A. Maggi, L. Pilerci, S. Mazzoni, A. Capone, M. Crupi, F. Cicogna, P. Boldrini, V. Tekle, S. Colao, M.G. Borella, M. Paoli, C. Rossolini, G.M. Vannucchi, A.M. Annunziato, F. Guglielmelli, P. Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy |
| title | Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy |
| title_full | Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy |
| title_fullStr | Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy |
| title_full_unstemmed | Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy |
| title_short | Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy |
| title_sort | humoral and cellular responses after third dose of sars-cov-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy |
| topic | Letter to Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226289/ https://www.ncbi.nlm.nih.gov/pubmed/37269750 http://dx.doi.org/10.1016/j.leukres.2023.107330 |
| work_keys_str_mv | AT atanasioa humoralandcellularresponsesafterthirddoseofsarscov2vaccineinmyeloproliferativeneoplasmspatientsonruxolitinibtherapy AT vannia humoralandcellularresponsesafterthirddoseofsarscov2vaccineinmyeloproliferativeneoplasmspatientsonruxolitinibtherapy AT maggil humoralandcellularresponsesafterthirddoseofsarscov2vaccineinmyeloproliferativeneoplasmspatientsonruxolitinibtherapy AT pilercis humoralandcellularresponsesafterthirddoseofsarscov2vaccineinmyeloproliferativeneoplasmspatientsonruxolitinibtherapy AT mazzonia humoralandcellularresponsesafterthirddoseofsarscov2vaccineinmyeloproliferativeneoplasmspatientsonruxolitinibtherapy AT caponem humoralandcellularresponsesafterthirddoseofsarscov2vaccineinmyeloproliferativeneoplasmspatientsonruxolitinibtherapy AT crupif humoralandcellularresponsesafterthirddoseofsarscov2vaccineinmyeloproliferativeneoplasmspatientsonruxolitinibtherapy AT cicognap humoralandcellularresponsesafterthirddoseofsarscov2vaccineinmyeloproliferativeneoplasmspatientsonruxolitinibtherapy AT boldriniv humoralandcellularresponsesafterthirddoseofsarscov2vaccineinmyeloproliferativeneoplasmspatientsonruxolitinibtherapy AT tekles humoralandcellularresponsesafterthirddoseofsarscov2vaccineinmyeloproliferativeneoplasmspatientsonruxolitinibtherapy AT colaomg humoralandcellularresponsesafterthirddoseofsarscov2vaccineinmyeloproliferativeneoplasmspatientsonruxolitinibtherapy AT borellam humoralandcellularresponsesafterthirddoseofsarscov2vaccineinmyeloproliferativeneoplasmspatientsonruxolitinibtherapy AT paolic humoralandcellularresponsesafterthirddoseofsarscov2vaccineinmyeloproliferativeneoplasmspatientsonruxolitinibtherapy AT rossolinigm humoralandcellularresponsesafterthirddoseofsarscov2vaccineinmyeloproliferativeneoplasmspatientsonruxolitinibtherapy AT vannucchiam humoralandcellularresponsesafterthirddoseofsarscov2vaccineinmyeloproliferativeneoplasmspatientsonruxolitinibtherapy AT annunziatof humoralandcellularresponsesafterthirddoseofsarscov2vaccineinmyeloproliferativeneoplasmspatientsonruxolitinibtherapy AT guglielmellip humoralandcellularresponsesafterthirddoseofsarscov2vaccineinmyeloproliferativeneoplasmspatientsonruxolitinibtherapy |